Developing a Novel Cytotoxic & Immunogenic Payload Class for the Next Generation of ADCs
9:30 am - Thursday 5th November 2026
- Examine the rationale for payloads that induce immunogenic cell death (ICD) rather than relying on conventional cytotoxic mechanisms alone
- Compare the activity of Ryvu's lead payload candidates against established ADC payloads across multiple tumor targets and models
- Understand how novel payload mechanisms can expand therapeutic opportunities, improve differentiation, and address emerging resistance in the ADC landscape
